Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab.
We describe an 18-year-old man with a 7-year history of severe major aphthous stomatitis refractory to multiple standard therapies who responded completely to therapy with adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor alpha (TNF-alpha).